ClinicalTrials.gg
RecruitingNCT06204705MEASURE-BDUpdated Nov 19, 2026

mHealth Estimate-based Algorithms Signaling Upcoming Recurrence of Episodes in Bipolar Disorders

An observational study in Bipolar Disorder, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by VA Office of Research and Development · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Bipolar Disorder by VA Office of Research and Development — 7 open to participants now, 7 under way, none of them phase 3. Bipolar Disorder · VA Office of Research and Development.

Started
2024
the only one that year
Observational
2 of 21
1 open now
Registered
17th of 21
by date

Among the 21 studies in Bipolar Disorder by VA Office of Research and Development, this one is the only one that started in 2024, is one of 2 observational ones, and was the 17th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

7 of the 21 studies in Bipolar Disorder by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Bipolar Disorder by VA Office of Research and Development, or all of them as a file.
02

Study summary

Veterans with bipolar disorders (BD) experience recurrent and seemingly unpredictable periods of severe impairments in psychosocial functioning, such as participation in social roles and activities. Many effective treatments for BD emphasize early detection of bipolar episodes, in order to make necessary treatment adjustments and prevent psychosocial impairments associated with acute mood episodes. Unfortunately, acute mood episodes in BD are also associated with a decrease in a patient's insight into their own symptoms, which can prevent one's ability to self-report first signs of symptoms and functional declines. Moreover, routine care visits for BD are typically too infrequent to capture and effectively monitor day-to-day changes in a patient's mood and functioning.

Objective, low-effort, and continuous methods of tracking symptoms and social participation of Veterans with BD in real-time and in-situ are needed to provide early (i.e., days in advance) warning signs of acute bipolar episodes and functional declines, which in turn would enable well-timed interventions to prevent poor psychosocial outcomes. mHealth refers to the use of mobile and wireless devices as part of patient care and offers many potential opportunities for early detection of and intervention for acute mood states in this population. However, these mHealth approaches have not been investigated in Veterans with BD. In a Small Projects in Rehabilitation Research (SPiRE)-funded pilot study, the investigator team established high feasibility and acceptability of one such innovative passive mHealth approach using a smartphone program, or an app, in a small sample of Veterans with BD to track their smartphone's GPS/location. The pilot study used a priori location context ratings of visited places (e.g., a priori ratings on types of activities usually engaged in at a frequently visited location) to derive unobtrusive measures of social participation (e.g., time spent at work-related locations). The goal of this Merit Review proposal is to establish reliable and valid machine-learning algorithms using the same types of mHealth data to prospectively (days in advance) detect declines in social participation and prospective onset of mania and depression in Veterans with BD. This proposal has three aims:

Aim 1. To establish a machine learning algorithm using GPS/location data for predicting prospective declines in social participation in Veterans with BD.

Aim 2. To establish machine learning algorithms using GPS/location data for predicting prospective acute BD clinical states. The investigators will explore whether adding more burdensome daily self-report and voice diaries' speech analysis features improves the models' precision using statistical indices of prediction precision or accuracy.

Aim 3. To explore clinical implementation of the mHealth-based algorithms in treatment of BD. Focus groups of VA providers and administrators will assess feasibility of algorithms' implementation in clinical care.

Read the detailed description

Veterans with bipolar disorders (BD) experience recurrent and seemingly unpredictable periods of severe impairments in psychosocial functioning, which lead to poor outcomes over their lifetime, such as incarceration, homelessness, and death by suicide. Studies support a link between greater severity and frequency of BD symptoms and worse psychosocial functioning. Veterans with BD often drop out of care at times when treatment would be most beneficial for preventing deterioration in psychosocial functioning-when new manic and depressive episodes onset. Thus, despite the availability of evidence-based treatments, BD is among the leading causes of disability worldwide.

Effective tools for prospectively detecting manic and depressive episode onset could provide clinicians with the opportunity to intervene more efficiently and prevent poor psychosocial outcomes and loss of life. Unsurprisingly, psychotherapeutic interventions often focus on teaching patients mood-monitoring techniques for episode relapse prevention. However, these self-report techniques require insight and high patient effort, which may be lacking during acute BD episodes. Real-world measures of both BD symptoms and social functioning in Veterans with BD that are objective and do not require high insight or high effort are missing. Thus, passive mHealth methods that are feasible and acceptable to Veterans with BD and effective in prospectively detecting onsets of both mania and depression could prevent psychosocial functioning declines by ensuring evidence-based care is provided at the times of greatest need.

The overarching goal of this Merit Award project is to establish reliable and valid machine-learning algorithms using mHealth data to prospectively detect declines in social participation and prospective onset of mania and depression in Veterans with BD. The study's specific aims are:

Aim #1. To establish a machine learning algorithm using GPS/location data for predicting prospective declines in social participation in Veterans with BD. The investigators will provide novel, real-world GPS-based machine learning models that predict days in advance changes in social participation in Veterans. Based on pilot data, the investigators expect GPS data predictors/features to include time spent at residence, work, and daily routine locations.

Aim #2. To establish machine learning algorithms using GPS/location data for predicting prospective acute BD clinical states. The investigators will explore whether adding more burdensome daily self-report and voice dairy features improves the models' accuracy using positive prediction and other statistical indices. The investigators predict passive GPS/location data alone will provide accurate prediction of prospective changes in BD symptoms.

Aim #3. To explore clinical implementation of the mHealth-based algorithms in treatment of BD. Focus groups of VA providers and administrators will assess feasibility of algorithms' implementation in clinical care.

To accomplish the aims, the study will recruit 200 Veterans with a BD diagnosis who receive care in the Minneapolis VA Health Care System through direct mailings to patients, flyers in the medical center, and referrals by clinicians. The study will use stratified sampling recruitment strategies for enrolling at least 20 Veterans in the age ranges 18-35, 36-45, 46-55, 56-65, and 66 and older. Participants will be followed for 14 weeks using three smartphone apps (i.e., VA mPRO, FollowMee, and Recorder Plus or ASR Voice Recorder). Daily, participants will complete an 8-question assessment of their current symptoms and provide voice data for speech analysis to a fixed prompt about their planned activities for the day. Another app will continuously and passively monitor location using the smartphone GPS features to detect deviations in daily routine. Biweekly, participants will complete a brief phone screen assessing social and community participation, symptoms of mania and depression, and suicidality. mHealth data from days prior to the biweekly interviews will be used as features in a small number of candidate machine learning models with outcome measures being biweekly interview assessments of bipolar symptoms and social participation. Project staff will also hold two focus groups-one of 8 VA mental health providers and one of 8 VA administrators-representing diverse disciplines and use guided discussion questions to elicit feedback about implementation of mHealth-based algorithms in future clinical care of Veterans with BD.

Impact: The study goal is to provide clinical tools for real-time, unobtrusive, and prospective signals about imminent depressive and manic episode relapses in Veterans with BD to their clinicians for more rapid, less costly, and more effective use of existing evidence-based treatments to prevent poor psychosocial functional outcomes. Moreover, the current study will yield objective, low effort, and unobtrusive measures for tracking social participation in-situ and in real-time in both Veterans with BD and other Veteran populations.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Bipolar Disorder
  • Veterans
  • Telemedicine
  • Digital Phenotyping
  • Machine Learning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Veterans with bipolar disorders who receive care at the Minneapolis VA Health Care System. VA providers and administrators who provide care to Veterans with bipolar disorders at the Minneapolis VA Health Care System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veteran participants will have a confirmed primary diagnosis of a Bipolar I Disorder, Bipolar II Disorder or Other Specified Bipolar Disorder (i.e., those with major depressive episodes and hypomania that meets all episode criteria but for duration) based on the clinical Interview for -Research Version (SCID-5-RV), medical chart review and consensus procedure directed by the PI
  • All Veteran participants will endorse presence of at least one bipolar episode in the last 12 months based on the interview and/or medical chart information
  • All Veteran participants will own a smartphone capable of running all study apps
  • All participants will be age 18 years or older
  • All participants will be fluent in English
  • All Veteran participants will be able to demonstrate capacity for consent (see below) and have no active court-appointed legal guardianship precluding ability to provide consent
  • Focus group participants will be active Minneapolis VAHCS providers and administrators who are either actively engaged in care for Veterans with BD or involved in administrative roles overseeing mental health care of Veterans within Minneapolis VAHCS

Exclusion criteria

Exclusion Criteria:

  • Presence of a major neurocognitive disorder or neurological disorder, such as Alzheimer's dementia, vascular dementia, Parkinson's disease, etc.
  • Impaired global cognition ( score \< 20 for in-person assessment, or equivalent score on "blind" MoCA for virtual assessments)
  • Presence of physical conditions preventing use of smartphone apps Lack of capacity to provide
  • Age \< 18 years
  • No exclusion for focus group participants as their VA status employment will be taken to indicate age of majority, intact global cognition, etc.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Veterans with Bipolar Disorders

    Veterans with a diagnosis of a bipolar disorder.

  • VA clinicians and administrators

    VA clinicians and administrators who provide or oversee clinical care of Veterans with bipolar disorders

06

What researchers measure

Primary outcomes

  1. Impaired Social Participation

    To determine presence of impaired social participation, an average of T scores will be calculated from two scales: PROMIS Satisfaction with Participation in Social Roles and PROMIS Ability to Participate in Social Roles and Activities scales. Averaged T scores less than 40 (1 standard deviation below population mean of 50) will be considered as indicators of impaired social participation. The PROMIS scales will be administered biweekly for the duration of 14 weeks of the follow-up.

    Time frame: Biweekly for 14 weeks

  2. Modified Hamilton Rating Scale for Depression

    Modified Hamilton Rating Scale for Depression interviews administered biweekly will assess depression symptoms for each week of the 14-week follow-up to assess presence of clinically significant depression (score of 14 or higher) and/or changes in depression severity.

    Time frame: Weekly for 14 weeks

  3. Young Mania Rating Scale

    Young Mania Rating Scale interviews administered biweekly will assess manic/hypomanic symptoms for each week of the 14-week follow-up period to determine presence of clinically significant hypomania/mania (scores above 12) and changes in hypomania/mania symptom severity.

    Time frame: Weekly for 14 weeks

  4. PROMIS Ability to Participate in Social Roles and Activities

    PROMIS Ability to Participate in Social Roles and Activities is a self-report measure of difficulties with social participation. The raw scores range from 8 to 40 with higher scores indicating greater difficulties with social participation. The raw scores will be transformed into T scores and then average with T score for PROMIS Satisfaction with Participation in Social Roles for each week of the follow-up. These average scores of T score less than 40 will be considered as indicators of impaired social participation during this week.

    Time frame: Biweekly for 14 weeks

Secondary outcomes

  1. DSI Suicidality Subscale

    Depressive Symptom Inventory Suicidality Subscale will assess presence of suicidal ideation and impulses in the prior two weeks during biweekly interviews for the duration of 14-week follow-up period. Exploratory analyses will assess ability to predict changes in suicidality symptoms using machine learning algorithms.

    Time frame: Biweekly for 14 weeks

Other outcomes

  1. VA Clinicians Focus Group Themes

    Focus groups of 8 VA clinicians who provide care to Veterans with bipolar disorders will be analyzed using a rapid qualitative analysis method to derive themes related to facilitators and inhibitors to clinical implementation of the mHealth methods and the study's machine learning algorithms in future clinical care of Veterans with bipolar disorders.

    Time frame: Once at a half-point of study's data collection (end of Year 2)

  2. VA Administrators Focus Group Themes

    Focus group of 8 VA administrators who oversee care for Veterans with bipolar disorders will be analyzed using a rapid qualitative analysis method to derive themes related to facilitators and inhibitors to clinical implementation of the mHealth methods and the study's machine learning algorithms in future clinical care of Veterans with bipolar disorders.

    Time frame: Once at the end of study's data collection (Year 4)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — PI will store all study research records and data for a minimum of 6 fiscal years post study closure as required by VA data retention policies. De-identified data will be stored for at least 7 years after publication of the project's findings and will be made available for data sharing when requests for sharing are made for scientific purposes (e.g., results validation purposes). When possible, written agreements will be used specifying conditions of data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Some supporting information, such as statistical analysis plan, may be shared prior to publication of results in online pre-registration open science websites. IPD and supporting information will be shared from the time of study results publication until 7 years after the publication for valid scientific reasons.

Access criteria: PI will share the IPD and supporting information in consultation with local Research office administrators for valid scientific purposes (e.g., validation of results, inclusion in mega-analysis or meta-analysis). PI will utilize VA approved methods at the time for online sharing of this type of information.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 95 non-industry observational studies under Bipolar Disorder, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's planned 36 months is below that.

Counting every sponsor, half of 105 studies reached it within 64 months; a quarter within 31 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 12, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06204705
Collaborators
National Center for PTSD, University of Wisconsin, Madison
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
Sep 10, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Snezana Urosevic, PhD
Contact
Snezana.Urosevic@va.gov
(612) 467-3897
Snezana Urosevic, PhD
principal investigator · Minneapolis VA Health Care System, Minneapolis, MN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion